How Eli Lilly's GLP-1 Drug Pipeline Is Reshaping the Pharma Landscape

The GLP-1 receptor agonist class of drugs has upended forecasts across the pharmaceutical sector. Eli Lilly's tirzepatide (Mounjaro/Zepbound) generated over $5 billion in 2024 revenue, while Novo Nordisk's semaglutide continues to dominate obesity treatment globally. Analysts project the global obesity drug market to exceed $100 billion by 2030. Beyond weight loss, these compounds are showing promise in cardiovascular disease, sleep apnea, and non-alcoholic fatty liver disease — widening the total addressable market considerably. Smaller biotechs are racing to develop oral GLP-1 formulations and next-generation peptides, attracting record venture funding.

Regulatory pipelines are also accelerating, with the FDA fast-tracking several obesity-adjacent indications. For investors and industry watchers, the pharma sector's pivot toward metabolic disease represents one of the most significant commercial opportunities in decades.